Prestige Consumer Healthcare (NYSE:PBH) Updates FY25 Earnings Guidance

Prestige Consumer Healthcare (NYSE:PBH) updated its FY25 earnings guidance on Thursday. The company provided EPS guidance of $4.40 to $4.46 for the period, compared to the consensus EPS estimate of $4.42. The company issued revenue guidance of $1.125 billion to $1.140 billion, compared to the consensus revenue estimate of $1.13 billion. Prestige Consumer Healthcare also updated its FY 2025 guidance to 4.460-4.460 EPS.

Analysts Set New Price Targets

A number of equities analysts have recently commented on the stock. Jefferies Financial Group reaffirmed a “hold” rating and set a $76.00 target price (up from $70.00) on shares of Prestige Consumer Healthcare in a research report on Tuesday, September 24th. DA Davidson upped their price target on Prestige Consumer Healthcare from $93.00 to $95.00 and gave the stock a “buy” rating in a research report on Wednesday, August 28th. Two analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat, Prestige Consumer Healthcare presently has an average rating of “Moderate Buy” and an average target price of $94.20.

Prestige Consumer Healthcare Stock Performance

NYSE:PBH traded up $1.97 during mid-day trading on Thursday, hitting $79.61. The company’s stock had a trading volume of 10,788 shares, compared to its average volume of 245,974. The business’s fifty day moving average is $72.31 and its two-hundred day moving average is $69.71. The company has a debt-to-equity ratio of 0.65, a current ratio of 3.23 and a quick ratio of 1.90. Prestige Consumer Healthcare has a 1 year low of $56.61 and a 1 year high of $79.82. The stock has a market cap of $3.95 billion, a price-to-earnings ratio of 18.93, a PEG ratio of 2.08 and a beta of 0.47.

Prestige Consumer Healthcare (NYSE:PBH) last posted its earnings results on Thursday, August 8th. The company reported $0.90 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.86 by $0.04. Prestige Consumer Healthcare had a net margin of 18.43% and a return on equity of 12.55%. The business had revenue of $267.10 million for the quarter, compared to analyst estimates of $260.54 million. During the same period in the prior year, the company posted $1.06 EPS. The company’s revenue for the quarter was down 4.4% on a year-over-year basis. Analysts anticipate that Prestige Consumer Healthcare will post 4.43 EPS for the current fiscal year.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.